Filter Results
:
(178)
Show Results For
-
All HBS Web
(178)
- People (1)
- News (53)
- Research (81)
- Events (3)
- Multimedia (9)
- Faculty Publications (50)
Show Results For
-
All HBS Web
(178)
- People (1)
- News (53)
- Research (81)
- Events (3)
- Multimedia (9)
- Faculty Publications (50)
- January 2016 (Revised January 2019)
- Supplement
The Allergan Board Under Fire (B)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund...
View Details
Keywords:
Allergan, Inc.;
Valeant;
Ackman;
Pershing Square;
Tender Offer;
Activist Investors;
Business Models;
R&D;
Board Of Directors;
Securities Litigation;
Acquisition Strategy;
Takeover Defenses;
Hedge Funds;
Shareholder Rights;
Proxy Contest;
Shareholder Special Meetings;
Legal Issues In Contested Takeovers;
Corporate Governance;
Investment Activism;
Business and Stakeholder Relations;
Business Model;
Business and Shareholder Relations;
Valuation;
Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (B)." Harvard Business School Supplement 316-029, January 2016. (Revised January 2019.)
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more...
View Details
Keywords:
Valuation;
Cash Flow;
Financing and Loans;
Business Startups;
Financial Strategy;
Medical Devices and Supplies Industry;
Pharmaceutical Industry;
Health Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- January 2016 (Revised January 2019)
- Case
The Allergan Board Under Fire (A)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund...
View Details
Keywords:
Allergan, Inc.;
Valeant;
Ackman;
Pershing Square;
Tender Offer;
Activist Investors;
Business Models;
R&D;
Board Of Directors;
Securities Litigation;
Acquisition Strategy;
Takeover Defenses;
Hedge Funds;
Shareholder Rights;
Proxy Contest;
Shareholder Special Meetings;
Legal Issues In Contested Takeovers;
Governing and Advisory Boards;
Mergers and Acquisitions;
Corporate Governance;
Management Teams;
Business and Shareholder Relations;
Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (A)." Harvard Business School Case 316-010, January 2016. (Revised January 2019.)
- September 2020
- Case
Minerva 2010: Turbulent Times
By: John R. Wells and Benjamin Weinstock
In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at...
View Details
Wells, John R., and Benjamin Weinstock. "Minerva 2010: Turbulent Times." Harvard Business School Case 721-390, September 2020.
- Web
Curriculum - MBA
this course is to enable students to explore entrepreneurship within the life sciences. Students will explore opportunities along various aspects of the R&D and commercialization lifecycle, along science, clinical, regulatory and commercial areas of the lifecycle....
View Details
- Web
Capstone - MBA
that will advance new drug discoveries and therapeutics with those equally passionate about changing the business of healthcare for the better. 2 The practicalities of business decisions meet the practicalities of hard science. Students...
View Details
- Web
Faculty & Advisors - MBA
Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), Korro Bio, Akouos (NASDAQ: AKUS), Gemini Therapeutics (NASDAQ: GMTX), Inipharm, and PACT Pharma. She was previously...
View Details
- Web
Overview - MBA
relevant timeframes, opportunity-costs, rewards, and organizational behavior. Assess the potential therapeutic value of discoveries emanating from lab-discovery in the life sciences and understand ways to accelerate these discoveries into...
View Details
- 12 Jul 2016
- First Look
July 12, 2016
spending. Whereas traditional (small-molecule) drugs have historically faced price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already...
View Details
Keywords:
Sean Silverthorne
- Web
Hiring Organizations
Cargill Carlyle Group, The Carrum Health Cartesian Capital Group Casa Verde Capital Causeway Capital Management Causeway Media Partners CAVA CBRE CBRE Global Investors Celonis Centerview Partners CenterWell Home Health Centroid Investment Partners Cepheid Cha View Details
- 01 Nov 2013
- HBS Seminar
Eric Olson, Chief Scientific Officer at Syros Pharmaceuticals
- May 2024
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting...
View Details
Keywords:
Health Care and Treatment;
Technological Innovation;
Product Development;
Health Testing and Trials;
Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics 115, no. 5 (May 2024): 988–992.
- 11 Oct 2011
- Working Paper Summaries
US Healthcare Reform and the Pharmaceutical Industry
- Web
Blavatnik Fellowship in Life Science Entrepreneurship - Health Care
venture capital firm. Since 2002, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. Prior to Atlas he was co-founder, executive vice president, and chief business officer of Celera...
View Details
- Web
Named Fellowship Funds - Alumni
Institute for Translational Medicine and Therapeutics at the School of Medicine of the University of Pennsylvania and on the board of Hope for New York. He received a BS in economics from the Wharton School of the University of...
View Details
- Web
Technology & Innovation - Faculty & Research
Clinical Trials by Pharmaceutical and Medical Device FirmsBy: Caroline Marra and Ariel D. Stern May 2024 | Article | Clinical Pharmacology & Therapeutics Digital health technologies (DHTs) can enable more patient-centric View Details
- 01 Dec 2023
- News
Wide Horizon
studies the relationship between the gut microbiome and ASD, and whose work N of One also supports. “That’s constricted funding and therefore growth in this field.” This microbiome research has led to a therapeutic (currently in Phase II...
View Details
Keywords:
Dan Morrell; Photos by Sarah Wilson
- Web
Health Care - Faculty & Research
Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device FirmsBy: Caroline Marra and Ariel D. Stern May 2024 | Article | Clinical Pharmacology & Therapeutics Digital health technologies (DHTs) can enable more...
View Details
- 01 Dec 2023
- News
Drop Everything, Read This
psychiatrist Palmer’s thesis that “mental disorders are metabolic disorders of the brain” provides new therapeutic pathways based on a rigorous synthesis of existing literature. Low-cost, low-risk lifestyle interventions include sleep,...
View Details
- Web
Mental Health - MBA
workers, psychologists, and psychiatrists who maintain private practices in the Harvard Square area and accept the student health insurance. These clinicians typically work with students who have an interest in a long-term therapeutic...
View Details